Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Ovarian cancer. Found 26 abstracts

no pagination
Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition. Cancer Biol Ther. 2019 Mar 30;20(7):1035-45.   PMCID: PMC6606007
Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 Aug;154(2):294-301.
Burger RA, Deng W, Makker V, Collins Y, Gray H, Debernardo R, Martin LP, Aghajanian C. Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Sep;150(3):466-70.
Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M. Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Invest New Drugs. 2018 Jun;36(3):476-86.
Capo-Chichi CD, Cai KQ, Xu XX. Overexpression and cytoplasmic localization of caspase-6 is associated with lamin A degradation in set of ovarian cancers. Biomarker research. 2018 Jan;6:30.   PMCID: PMC6208109
Eskander RN, Kauderer J, Tewari KS, Mannel RS, Bristow RE, O'Malley DM, Rubin SC, Glaser GE, Hamilton CA, Fujiwara K, Huh WK, Ueland F, Stephan JM, Burger RA. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 Jun;149(3):525-30.
Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol. 2018 Mar;148(3):507-14.
Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 Oct;151(1):46-52.
Patel NR, Piroyan A, Ganta S, Morse AB, Candiloro KM, Solon AL, Nack AH, Galati CA, Bora C, Maglaty MA, O'Brien SW, Litwin S, Davis B, Connolly DC, Coleman TP. In Vitro and In Vivo evaluation of a novel folate-targeted theranostic nanoemulsion of docetaxel for imaging and improved anticancer activity against ovarian cancers. Cancer Biol Ther. 2018 Jul 03;19(7):554-64.   PMCID: PMC5989790
Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRalpha) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRalpha-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 Nov;147(2):402-7.
Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jun;137(3):386-91.   PMCID: 4447525
Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, Anderson GL. Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecol Oncol. 2015 Nov;139(2):253-60.   PMCID: PMC4664187
von Mehren M, Bookman M, Meropol NJ, Weiner LM, Sherman E, Li J, Knoblauch R, Parekh T, Cohen RB. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 2015 May;75(5):1047-55.   PMCID: 4978949
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecol Oncol. 2014 Jun;133(3):584-90.
Randall LM, Sill MW, Burger RA, Monk BJ, Buening B, Sorosky JI. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial. Gynecologic Oncology. 2012 Mar;124(3):563-8.   PMCID: PMC3278517
Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group study. Gynecologic Oncology. 2012 Jan;124(1):53-8.   PMCID: *
Adams SF, Marsh EB, Elmasri W, Halberstadt S, VanDecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC, Belsadron G, Biochimie V P. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecologic Oncology. 2011 Dec;123(3):486-91.   PMCID: PMC3260049
Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-alpha 5 beta 1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecologic Oncology. 2011 May;121(2):273-9.   PMCID: not NIH funded
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
Maradeo ME, Cairns P. Translational application of epigenetic alterations: Ovarian cancer as a model. Febs Letters. 2011 Jul;585(13):2112-20.   PMCID: PMC3129436
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Ovarian cancer

Ovarian cancer carcinoma PARP inhibitor survival Clinical trial genetics Trabectedin Ovarian Neoplasms Antibody-drug conjugate Bevacizumab Phase II trial BRCA1 Genes tumors Female Veliparib Peritoneal Neoplasms tyrosine kinase inhibitor drug therapy cisplatin trial therapeutic use Pegylated Liposomal Doxorubicin BRCA2 mutation BRCA1 Mice microrna expression profiles nanoemulsions CA-125 Surgeon's assessment folic acid Combination therapy human breast-cancer folate receptor-alpha independent prognostic-factor Tumor Cell Line primary cytoreductive surgery Docetaxel BRCA mutations Florida Miami (UM) Miller Medical School in Miami-USA Springer Nature remains dna methylation Polyethylene Glycols guidelines analogs & derivatives Flow cytometry cell death progression liposomal platinum-resistant Risk prediction triple angiokinase inhibitor phase-ii Platinum sensitive affiliations adverse effects Folate receptor alpha Phase II Xenograft Model Antitumor Assays tumor-suppressor gene alpha(5)beta(1) integrin 1987 en ss-gynecologic oncology-v27-p368 Ca125 Lymphadenopathy Combination chemotherapy BRCA1 Protein ca125 response criteria BRCA1 lung-cancer Methylation Platinum resistant topotecan Dalantercept oncology-group platinum Adult Volociximab interest is to be reported by the authors This study was carried out in Toxicity brca1 promoter laboratory of Dr Callinice D Capo-chichi in the university of Abomey Calavi Middle Aged fibroblast-growth-factor Active caspase-6 80 and over Aged Cytoplasmic localization oophorectomy Radiographic evaluation theranostic progression-free survival stem-like cells Local Neoplasm Recurrence Fallopian Tube Neoplasms phase-ii trial sporadic breast cell circulating tumor-cells Soft tissue sarcomas Surgical cytoreduction C degradation He4 alpha 5 beta 1 integrin Nrg Animal Disease Models 2 mutations Ipafricept Sarcoma resistance chemotherapy Anti-angiogenic therapy therapy angiogenesis Brca immunogenicity solid Lamin A drug effects ca 125 induction chemotherapy doxorubicin lymphadenectomy Gog neutral with regard to jurisdictional claims in published maps and institutional half-life Cell Survival node involvement region Antineoplastic Antibiotics Transaminases epithelial ovarian (UAC) in Benin and in the laboratory of Dr Xiang-Xi Xu in the University of obtained for this study using archived tissuesNot applicableNo competing imatinib mesylate Bilirubin Phase I Advanced malignancies T-Lymphocytes Response assessment Translational research gynecologic-oncology-group bevacizumab immunology BRCA2 Genes Histone modification HSP90 inhibitor Immunofluorescence cpg-island hypermethylation fibronectin docetaxel Hepatic impairment BRCA2 Protein covalent histone modifications Immunomodulation
Last updated on Friday, January 03, 2020